Display screen or portion thereof with graphical user interface

- Guardant Health, Inc.
Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

FIG. 1 is a front view of a first embodiment of a display screen or portion thereof with a graphical user interface showing of our new design;

FIG. 2 is a front view of a second embodiment of a display screen or portion thereof with a graphical user interface showing of our new design;

FIG. 3 is a front view of a third embodiment of a display screen or portion thereof with a graphical user interface showing of our new design; and,

FIG. 4 is a front view of a fourth embodiment of a display screen or portion thereof with a graphical user interface showing of our new design.

The dot-dash-dot broken lines illustrate a display screen, which is the environment of the design, and which forms no part of the claimed design. The remaining broken lines illustrate portions of the graphical user interface, and form no part of the claimed design.

Claims

The ornamental design for a display screen or portion thereof with a graphical user interface, as shown and described.

Referenced Cited
U.S. Patent Documents
D810111 February 13, 2018 Garcia
D1049146 October 29, 2024 Shah
D1050165 November 5, 2024 Shah
20140287937 September 25, 2014 So et al.
20170240973 August 24, 2017 Eltoukhy et al.
20170260590 September 14, 2017 Eltoukhy
20180300456 October 18, 2018 Eltoukhy
20180305738 October 25, 2018 Kennedy
20200308656 October 1, 2020 Lewin et al.
20210057046 February 25, 2021 Liu et al.
20240052419 February 15, 2024 Eltoukhy
20240071628 February 29, 2024 Eltoukhy
20240153593 May 9, 2024 Eltoukhy
Foreign Patent Documents
2013190441 December 2013 WO
2014039556 March 2014 WO
2014043763 March 2014 WO
2014165549 October 2014 WO
Other references
  • Tumor Response Map, posted Aug. 18, 2016 [online], [retrieved Oct. 19, 2023]. Retrieved from internet, https://web.archive.org/web/20210508233308/https://dribbble.com/shots/2907808-Tumor-Response-Map (Year: 2016).
  • Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome, posted Sep. 19, 2020 [online], [retrieved Oct. 19, 2023]. Retrieved from internet, https://www.sciencedirect.com/science/article/pii/S2666364320 (Year: 2020).
  • “Guardant Complete”, posted date unavailable [online], [retrieved May 28, 2024]. Retrieved from internet, https://www.guardantcomplete.com/why-guardant/product-portfolio-testing-evidence (Year: 2024).
  • Chan, K.C.A et al. “Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing” PNAS (2013) 110(47):18761-18768.
  • European Office Action for EP Application No. 22176398.0, dated Aug. 30, 2023.
  • Non-final Office Action for U.S. Appl. No. 17/462,906, dated Aug. 16, 2023.
  • Non-Final Office Action for U.S. Appl. No. 17/699,968 dated Sep. 8, 2023.
  • Office Action for U.S. Appl. No. 17/822,058 mailed Jun. 27, 2023.
  • Ding, L. et al. “Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing” Nature (2012) 481(7382):506-510.
  • Forshew, T. et al. “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA” Sci Transl Med (2012) 4(136) ra68.
  • Gerlinger, M. et al. “Intratumor heterogeneity and Branched Evolution Revealed by Multiregion Sequencing” New England J Medicine (2012) 366(10):883-892.
  • Guardant Health Inc. vs. Foundation Medicine GmbH regarding EP3240911B1, Statement of Defense dated Nov. 8, 2021.
  • Brocks, D. et al. “Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer” Cell Rep. Aug. 7, 2014;8(3):798-806.doi: 10.1016/j.celrep.2014.06.053. Epub Jul. 24, 2014.
  • Final Office Action for U.S. Appl. No. 17/699,968, dated Dec. 7, 2022.
  • Kivioja, T., et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. Nov. 20, 2011;9(1):72-4. doi: 10.1038/nmeth. 1778.
  • Kivioja, T., et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. Nov. 20, 2011;9(1):72-4. doi: 10.1038/nmeth. 1778. Supplementary Material.
  • Pan, H. et al. “Epigenomic evolution in diffuse large B-cell lymphomas” Blood (2013) 122(21):634.
  • Sharma, S.V. et al. “A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations” Cell (2010) 141(1):69-80.
  • Stefansson, O.A. et al. “Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine” Am J Pathology (2013) 183(4):1052-1063.
  • Final Office Action in U.S. Appl. No. 15/431,395, dated Apr. 28, 2023.
  • Office Action for U.S. Appl. No. 17/822,058, dated Mar. 10, 2023.
  • Dingli, D. et al. “(A)Symmetric Stem Cell Replication and Cancer” PLoS Comp Biology (2007) 3(3):e53 482-487.
  • Ekundayo, B. et al. “Origins of DNA replication” PLoS Genetics (2019) 15(9):e108320, 1-20.
  • Final Office Action for U.S. Appl. No. 17/462,906, dated Mar. 13, 2024.
  • Final Office Action for U.S. Appl. No. 17/822,058 dated Apr. 9, 2024.
  • Final Office Action in U.S. Appl. No. 17/822,058, mailed Sep. 28, 2023.
  • Office Action for U.S. Appl. No. 17/818,944 dated Dec. 7, 2023.
  • Pinkel, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. Oct. 1998;20(2):207-11.
  • Dileep, V. et al. “Single-cell replication profiling to measure stochastic variation in mammalian replication timing” Nature Com (2018) 9:427.
  • Final Office Action for U.S. Appl. No. 17/818,944 dated Sep. 25, 2024.
  • Liu, B. et al. “Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges” Oncotarget (2013) 4(11):1868-1881.
  • Luo, H. et al. “Genome-wide estimation of firing efficiencies of origins of DNA replication from time-course copy number variation data” BMC Bioinformatics (2010) 11:247 (15 pages).
  • Office Action for U.S. Appl. No. 15/431,395 mailed Jul. 19, 2024.
Patent History
Patent number: D1077824
Type: Grant
Filed: Feb 2, 2021
Date of Patent: Jun 3, 2025
Assignee: Guardant Health, Inc. (Palo Alto, CA)
Inventors: Helmy Eltoukhy (Atherton, CA), AmirAli Talasaz (Atherton, CA), Bahram Ghaffarzadeh Kermani (Los Altos, CA), Nnamdi Ihuegbu (San Francisco, CA)
Primary Examiner: Christian P. McLean
Assistant Examiner: Emilee Voigt
Application Number: 29/768,979
Classifications
Current U.S. Class: Generated Image (D14/485)